PCSK9 Gene Editing for Long-Lasting LDL Cholesterol Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypercholesterolemia and cardiovascular disease associated with PCSK9, such as antibody-based therapeutics and RNAi-based therapeutics, do not provide long-lasting inhibition of PCSK9, necessitating the development of more effective methods.
Innovation Solution
Utilizing the CRISPR/Cas system with guide RNAs to target and edit the PCSK9 gene, reducing PCSK9 expression and increasing LDL receptor levels, thereby lowering LDL cholesterol levels and treating hypercholesterolemia and cardiovascular disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based therapeutics or RNAi-based therapeutics are used to inhibit PCSK9, then PCSK9 inhibition is achieved, but the inhibition duration is insufficient and requires frequent administration
Solution Approach 1:
The patent replaces the mechanical/biological system of antibody-RNAi therapeutics with a genomic editing system (CRISPR/Cas9). Instead of using external molecules that need repeated administration, the invention directly edits the PCSK9 gene DNA sequence to create permanent loss-of-function mutations, substituting a one-time genetic modification for recurring pharmacological treatments.
Solution Approach 2:
The patent performs preliminary action by permanently modifying the PCSK9 gene before any therapeutic effect is needed. The CRISPR/Cas9 system introduces definitive genetic mutations (such as frameshift mutations or premature stop codons) that permanently abolish PCSK9 function, eliminating the need for repeated administrations required by antibody or RNAi therapies.
2Duration of action of stationary object
If CRISPR/Cas9 system is used to edit PCSK9 gene, then long-lasting inhibition is achieved, but delivery efficiency and off-target effects become critical challenges
Solution Approach 1:
The patent applies parameter changes by systematically optimizing multiple variables: guide RNA sequence design to enhance target specificity and binding affinity, Cas9 protein variants with improved fidelity to reduce off-target effects, delivery vehicle parameters (lipid composition, particle size), and dosing parameters. These parameter optimizations collectively improve both delivery efficiency and therapeutic safety.
Solution Approach 2:
The patent introduces intermediaries to facilitate safe and efficient gene delivery. Lipid nanoparticles serve as intermediary carriers that protect CRISPR components during circulation and enable cellular uptake. Additionally, intermediary guide RNA sequences are designed with high specificity to ensure precise target recognition and minimize off-target genomic modifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CRISPR/Cas system achieves long-lasting reduction of PCSK9 protein production, enhancing LDL receptor abundance, and effectively lowering LDL cholesterol levels, thereby treating hypercholesterolemia and reducing the risk of cardiovascular disease.
Implementation Method 1
Compositions and methods to reduce the expression of the PCSK9 gene using CRISPR/Cas system
Implementation Method 2
novel guide RNA (gRNA) with high editing efficiency can knockout or knock down mutant or wildtype PCSK9 gene expression
Data Source
AI summary
Compositions and methods are described herein for treating subjects having hypercholesterolemia and/or cardiovascular disease.